Agilent Technologies (NYSE:A) Stock Gets Price Target Increase from Barclays

Agilent Technologies (NYSE:A) had its price target hoisted by equities researchers at Barclays from $175.00 to $195.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price points to a potential upside of 15.01% from the company’s current price.

Several other analysts have also recently issued reports on A. Royal Bank Of Canada upped their target price on Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. TD Cowen raised their price objective on shares of Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Piper Sandler started coverage on shares of Agilent Technologies in a research note on Thursday, June 11th. They set a “neutral” rating and a $150.00 target price on the stock. Wall Street Zen lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday. Finally, UBS Group assumed coverage on shares of Agilent Technologies in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $165.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.44.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $169.54 on Wednesday. The company has a 50 day moving average price of $154.04 and a 200 day moving average price of $134.38. The firm has a market capitalization of $47.80 billion, a P/E ratio of 33.56, a PEG ratio of 2.61 and a beta of 1.21. The company has a quick ratio of 1.56, a current ratio of 2.05 and a debt-to-equity ratio of 0.50. Agilent Technologies has a 52 week low of $108.35 and a 52 week high of $177.05.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. During the same period last year, the firm posted $1.37 EPS. Agilent Technologies’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Sell-side analysts expect that Agilent Technologies will post 6.2 EPS for the current year.

Insiders Place Their Bets

In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of Agilent Technologies stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the sale, the director directly owned 4,924 shares in the company, valued at $745,395.12. This trade represents a 11.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Hedge Funds Weigh In On Agilent Technologies

Several hedge funds have recently bought and sold shares of the company. Greenleaf Trust grew its holdings in shares of Agilent Technologies by 0.8% in the second quarter. Greenleaf Trust now owns 8,117 shares of the medical research company’s stock valued at $1,078,000 after purchasing an additional 68 shares in the last quarter. Nilsine Partners LLC raised its stake in Agilent Technologies by 0.8% during the second quarter. Nilsine Partners LLC now owns 9,650 shares of the medical research company’s stock valued at $1,282,000 after purchasing an additional 72 shares in the last quarter. Sapient Capital LLC lifted its position in Agilent Technologies by 4.2% during the first quarter. Sapient Capital LLC now owns 2,105 shares of the medical research company’s stock valued at $240,000 after purchasing an additional 85 shares during the last quarter. Integrated Wealth Concepts LLC lifted its position in Agilent Technologies by 0.8% during the second quarter. Integrated Wealth Concepts LLC now owns 11,555 shares of the medical research company’s stock valued at $1,535,000 after purchasing an additional 88 shares during the last quarter. Finally, UNIVEST FINANCIAL Corp grew its stake in shares of Agilent Technologies by 1.3% in the 2nd quarter. UNIVEST FINANCIAL Corp now owns 7,145 shares of the medical research company’s stock worth $949,000 after buying an additional 93 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.